{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-001060","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.930056+00:00","generated_at":"2026-05-16T10:44:59.707720+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel prelim 2025 revenue $276M (+23% Q4); MACI rev $239.5M; GAAP net profitable 2nd year","bullets":["Total revenue ~$276M; MACI $239.5M (+20%+ YoY 3rd consecutive yr); Burn Care $36.5M.","Gross margin 74%; adj. EBITDA margin 26%; $200M cash & investments, no debt.","Q4 set records for MACI implants, implanting surgeons, biopsies; >900 MACI Arthro trained surgeons.","Completed sales force expansion; initiated MACI Ankle MASCOT trial; new mfg facility on track for 2026.","CEO cites strong execution, expects continued high revenue growth and profitability improvement in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-001060","json":"https://secwatch.observer/filing/0001140361-26-001060.json","markdown":"https://secwatch.observer/filing/0001140361-26-001060.md","text":"https://secwatch.observer/filing/0001140361-26-001060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/0001140361-26-001060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:44:59.707720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}